Six weeks after cell and gene therapy manufacturer Cellares revealed that Bristol Myers Squibb would use its innovative robotic production program, the companies have expanded their association. BMS ...
Bristol Myers Squibb and Cellares announced Monday a worldwide capacity reservation and supply agreement for the manufacturing of CAR T cell therapies. The transaction is valued at up to $380 million ...
On April 4, 2024, Bristol Myers Squibb (“BMS”) and 2seventy bio, Inc. announced that the FDA has approved ABECMA (idecabtagene vicleucel) for the treatment of adult patients with relapsed or ...
At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results